{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
deferoxamine
to a specific field?
Status:
US Approved Rx
(2017)
Source:
ANDA207384
(2017)
Source URL:
First approved in 1968
Source:
NDA016267
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Deferoxamine (brand name Desferal) an iron chelator, is a drug for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Deferoxamine chelates iron by forming a stable complex that prevents the iron entering into further chemical reactions. However, drug may cause hypersensitivity reactions, systemic allergic reactions, and cardiovascular, hematologic and neurological adverse reactions. Serious adverse reactions include significant hypotension and marked body weight loss. Principally plasma enzymes metabolize deferoxamine, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.
Status:
US Approved Rx
(2017)
Source:
ANDA207384
(2017)
Source URL:
First approved in 1968
Source:
NDA016267
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Deferoxamine (brand name Desferal) an iron chelator, is a drug for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Deferoxamine chelates iron by forming a stable complex that prevents the iron entering into further chemical reactions. However, drug may cause hypersensitivity reactions, systemic allergic reactions, and cardiovascular, hematologic and neurological adverse reactions. Serious adverse reactions include significant hypotension and marked body weight loss. Principally plasma enzymes metabolize deferoxamine, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.
Status:
US Approved Rx
(2017)
Source:
ANDA207384
(2017)
Source URL:
First approved in 1968
Source:
NDA016267
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Deferoxamine (brand name Desferal) an iron chelator, is a drug for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Deferoxamine chelates iron by forming a stable complex that prevents the iron entering into further chemical reactions. However, drug may cause hypersensitivity reactions, systemic allergic reactions, and cardiovascular, hematologic and neurological adverse reactions. Serious adverse reactions include significant hypotension and marked body weight loss. Principally plasma enzymes metabolize deferoxamine, but the pathways have not yet been defined. The chelate is readily soluble in water and passes easily through the kidney, giving the urine a characteristic reddish color. Some is also excreted in the feces via the bile.
Status:
Investigational
Source:
NCT00691548: Phase 1 Interventional Completed Stage IV Cancer
(2009)
Source URL:
Class:
PROTEIN
ZIRCONIUM ZR-89 is used in specialized diagnostic applications using positron emission tomography (PET). An increasing interest in zirconium-89 can be attributed to the isotope's half-life, which is compatible with antibody imaging. ZR-89 as a radioimmunoconjugate, [89Zr]DFO-HuMab-5B1 was used in preclinical animal models of lung, colorectal, and pancreatic malignancies for PET imaging and was in a phase I trial for pancreatic cancer. In addition, the use of 89Zr-DFO-nimotuzumab that had low organ absorbed dose and effective dose made it suitable for potential human use for immunoPET imaging of epidermal growth factor receptor I. It is known, that epidermal growth factor receptor upregulation is associated with enhanced proliferation and drug resistance in a number of cancers.
